Global Immune Cell Engineering Market Size To Exceed USD 31.50 Billion By 2035 | CAGR Of 22.27%

Global Immune Cell Engineering Market Size To Exceed USD 31.50 Billion By 2035

According to a research report published by Spherical Insights & Consulting, The Global Immune Cell Engineering Market Size is Expected To Grow from USD 3.45 Billion in 2024 to USD 31.50 Billion by 2035, at a CAGR of 22.27% during the forecast period 2025-2035.

Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the "Global Immune Cell Engineering Market Size, Share, and COVID-19 Impact Analysis, By Cell Type (T Cells, NK Cells, Dendritic Cells, Tumor Cells, Stem Cells, and Others), By End User Type (Research Institutes, Biotechnological & Pharmaceutical Organizations, Diagnostic Centres or Labs, and Academics or Educational Centres), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. " Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/immune-cell-engineering-market

The Immune Cell Engineering Market Size is the sector emphasizing the use of engineering principles to modify immune cells, like T-cells and natural killer cells, for therapeutic purposes. Immune cell engineering is a new discipline that aids in creating engineering tools to both investigate and change the immune system. It is a revolutionary tool, as dysfunction of the immune system plays an important role in several diseases, ranging from inflammation to cancer via autoimmunity and transplant rejection. Vaccines like nicotine vaccines are constructed by immune engineering out of a range of diverse materials, like liposomes carrying DNA to protect against malaria, and biodegradable polymeric nanoparticles. Further, ongoing clinical and preclinical studies for modifying the fate and function of immune cells for applications like cancer and infectious disease are providing growth opportunities in immune cell engineering market. The immune cell engineering market is driven by the growing prevalence of autoimmune diseases, especially in developing countries. Surging advancements in CAR-T cell therapy, which is due to the development of cutting-edge gene engineering tools, are contributing to propel market demand. On the contrary, increased cost and regulatory complexities, which are limiting patient accessibility to advanced treatments, are challenging the market growth of immune cell engineering.

The T cells segment dominated the market with a significant market share of about 30.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the cell type, the immune cell engineering market size is divided into T cells, NK cells, dendritic cells, tumor cells, stem cells, and others. Among these, the T cells segment dominated the market with a significant market share of about 30.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Genetically engineered T cell immunotherapy provides remarkable clinical success for treating B cell acute lymphoblastic leukemia by harnessing patients’ own T cells to kill cancer, providing therapeutic benefit for cancer, infectious diseases, and autoimmunity. An upsurge in advancements in gene editing by enabling more precise genetic manipulation for enhancing T cell engineering and function is propelling the market growth.

The biotechnological & pharmaceutical organizations segment accounted for the largest share of about 58.5% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the end user type, the immune cell engineering market is divided into research institutes, biotechnological & pharmaceutical organizations, diagnostic centres or labs, and academics or educational centres. Among these, the biotechnological & pharmaceutical organizations segment accounted for the largest share of about 58.5% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. An increasingly innovative approach by companies like AstraZeneca, providing an opportunity for delivery next next-generation therapeutics, is driving the market growth in the biotechnological & pharmaceutical organizations segment. Immune cells act as a living drug, approved for treating hematologic malignancies.

North America is expected to hold the majority share of the global immune cell engineering market during the forecast period.

North America is expected to hold the majority share, ranging between 40-53% in the global immune cell engineering market during the forecast period. United States is the dominant country in the North America immune cell engineering market, accounting for nearly 80-90% in 2024, driven by increasing government support towards cell therapy programs. For instance, in October 2025, the US government pumped money into in vivo cell therapy programs. The market ecosystem in North America is strong, due to cutting-edge startups like Eradivir, Modulo Bio, Cellinfinity Bio, Liberate Bio, focusing on innovative cell therapy. The region's increased adoption of immunotherapies, along with the presence of biopharma companies and cancer research, is driving the immune cell engineering market.

Asia Pacific is anticipated to grow at the fastest pace of CAGR 22.5% in the global immune cell engineering market size during the forecast period. China is dominating the Asia Pacific immune cell engineering market during the forecast period, due to an exponential rise in clinical R&D activities and the development of innovative drugs and therapies. The Asia Pacific area has a thriving market for immune cell engineering due to increasing biotech innovation, along with an increasing advancement in regenerative medicine. The growing development of immune cell therapies by biotech companies is promoting the immune cell engineering market.

Major vendors in the global immune cell engineering market are Bristol-Myers Squibb, Novartis, Kite Pharma, AbbVie, Adicet Bio, Autolus Therapeutics, Bellicum Pharmaceuticals, Bluebird Bio, Celyad, Gilead Sciences, ImmunoCellular Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sorrento Therapeutics, TCR2 Therapeutics, and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Key Market Development 

• In November 2025, Ailux, Lilly partnered to advance bispecific antibody development. Through this collaboration, Lilly would gain access to Ailux's AI-powered bispecific antibody engineering platform.

• In May 2025, REPROCELL, a global leader in providing products and services, introduced StemEdit Human iPSC non-HLA class 1 and StemEdit Human iPSC non-HLA class 1/2 (B2M/CIITA Homo double KO) cell lines.

• In March 2025, AstraZeneca commit up to $11B+ to Chinese Collaborations, Beijing R&D hub. Pharma giant launches drug and vaccine partnerships with Harbour Biomed, Syneron Bio, and BioKangtai; Plans $2.5M Beijing R&D Hub; and alliance with Beijing Cancer Hospital.

• In January 2025, Cell BioEngines, Inc., a clinical-stage biotechnology company developing a universal ‘plug-and-play’ allogenic stem cell therapy platform and a portfolio of ‘off-the-shelf’ cell therapies for the treatment of hematologic and solid tumor malignancies, announced that it has signed a new lab lease at the Center for Engineering and Precision Medicine (CEPM), launched by the Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the immune cell engineering market based on the below-mentioned segments:

Global Immune Cell Engineering Market, By Cell Type

• T Cells
• NK Cells
• Dendritic Cells
• Tumor Cells
• Stem Cells
• Others

Global Immune Cell Engineering Market, By End User Type

• Research Institutes
• Biotechnological & Pharmaceutical Organizations
• Diagnostic Centres or Labs
• Academics or Educational Centres

 Global Immune Cell Engineering Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter